Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Vifor Becomes A 'Pure Play' Pharma

Apr 10 2017

• By John Davis

Related Content

AZ’s ZS-9 Targets Hyperkalemia Sector As It Nears EU Market

Feb 24 2017

Deal Watch: Teva's Sol Barer Leads Buyout Of IO Start-up NexImmune

Feb 22 2017

AstraZeneca’s ZS-9 Delay In US Gives Veltassa An Edge

Mar 20 2017

Related Companies

CSL Vifor

Pfizer Inc.

Relypsa, Inc.

AstraZeneca PLC

ChemoCentryx, Inc.

CSL Vifor

Additional Topics

Financing Business Strategies Companies Commercial Renal BioPharmaceutical

More from Financing

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window